Steris (BSP:S1TE34) Notes Receivable: R$0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:S1TE34 Steris PLC BSP:S1TE34
23 GF Score
Price R$52.14
GF Value R$60.72
! 1 Warning Sign
View Full Analysis

What is Steris Notes Receivable?

Steris BSP:S1TE34 23 Notes Receivable is R$0 Mil as of Mar. 2026. GuruFocus rates BSP:S1TE34 with a GF Score™ of 23/100 and a GF Value™ of R$60.72. The stock has 1 warning sign investors should review.

Steris's Notes Receivable for the quarter that ended in Mar. 2026 was R$0 Mil.

Steris Notes Receivable Historical Data

* Premium members only.

The historical data trend for Steris's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steris Notes Receivable Chart

Steris Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Steris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:S1TE34
23GF Score
Steris PLC BSP:S1TE34
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steris Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of R$0 Mil mean?
Steris (BSP:S1TE34) has a Notes Receivable of R$0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Steris and its competitors.
Is Steris' Notes Receivable too high?
Steris' current Notes Receivable is R$0 Mil. Overall, Steris has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Steris' Notes Receivable compare to ZBH and GEHC?
Steris' Notes Receivable of R$0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Steris and its competitors. Steris's current Notes Receivable is R$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Steris (BSP:S1TE34) has a current Notes Receivable of R$0 Mil. The stock's GF Value™ is R$60.72, compared to a current price of R$52.14 — trading 14.1% below its estimated fair value. The current Notes Receivable is R$0 Mil. Steris' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Steris (BSP:S1TE34), the current Notes Receivable is R$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Steris (BSP:S1TE34) Overvalued in 2026?

Based on GuruFocus' analysis, Steris stock appears to be undervalued. The current stock price of R$52.14 is trading 14.1% below its estimated GF Value™ of R$60.72.

Key valuation signals for BSP:S1TE34:

  • Notes Receivable: R$0 Mil
  • GF Value™: R$60.72 vs. price of R$52.14 (14.1% below fair value)
  • GF Score™: 23/100 with 1 warning sign

No single metric tells the full story. See the BSP:S1TE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Steris Business Description

Other Exchanges STE:USA2TG:Germany
Address 70 Sir John Rogerson\'s Quay, Dublin, IRL, D02 R296
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
23GF Score

Get the complete analysis for BSP:S1TE34

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$52.14
Price
R$60.72
GF Value